

COOPERATION TREATMENT COOPERATION TREATMENT COOPERATION TREATMENT 2005

EC'D 0 4 JAN 2005

PCT

WIPO .

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70) 10/541604

,	licant's or agent's file	e reference	FOR FURTHER	ACTION	0 5				
P 6	P 65123				See Form PCT/IPEA/416				
			International filing date 16.01.2004	e (day/month/year)	Priority date (day/month/year) 17.01.2003				
International Patent Classification (IPC) or national classification and IPC CO7D495/04, C07D295/04									
Applicant KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO et al.									
1.	This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.								
2.	This REPORT consists of a total of 4 sheets, including this cover sheet.								
3.	This report is also accompanied by ANNEXES, comprising:								
	a. Sent to the applicant and to the International Bureau) a total of sheets, as follows:								
	sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).								
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.								
	b. (sent to the International Bureau only) a total of (Indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).								
4.	This report contains indications relating to the following items:								
	図 Box No. I	Basis of the opin	ion						
	☐ Box No. II	Priority							
	☐ Box No. III	Non-establishme	ent of opinion with rega	ard to novelty, inventive step and industrial applicability					
	☐ Box No. IV	Lack of unity of in			,				
	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement								
	☐ Box No. VI	Certain documer							
	Box No. VII		n the international app						
	□ Box No. VIII	Certain observati	ions on the internation	al application					
Date	of submission of the	demand		Date of completion of t	ihls report				
17.0	8.2004			30.12.2004					
Name	e and mailing addres ninary examining au	ss of the internationa thority:	1	Authorized Officer	as Pitter.				
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465				Baston, E Telephone No. +49 89	2399-8229				



International application No. PCT/EP2004/000299

	Box	No. I	Basis of the re	port			
1.	With filed,	regard unless	to the language otherwise indica	e, this report is based of ated under this item.	on the international application in the language in which it was		
This report is based on translations from the original which is the language of a translation furnished			port is based on s the language o	translations from the c f a translation furnishe	original language into the following language , ed for the purposes of:		
		 □ international search (under Rules 12.3 and 23.1(b)) □ publication of the international application (under Rule 12.4) □ international preliminary examination (under Rules 55.2 and/or 55.3) 					
2.	have	been i	furnished to the r	* of the international a eceiving Office in resp d are not annexed to to	application, this report is based on <i>(replacement sheets which ponse to an invitation under Article 14 are referred to in this this report)</i> :		
	Desci	ription,	, Pages				
	1-18			as originally filed			
	Claim	ıs, Nun	nbers	•			
	1-10	1-10		as originally filed	•		
	□ а	a seque	ence listing and/o	r any related table(s) -	- see Supplemental Box Relating to Sequence Listing		
3.		_					
		☐ the o	description, page claims, Nos.				
			drawings, sheets sequence listing				
				o sequence listing <i>(spe</i>	pecify):		
4.	had n	not bee	oort has been es n made, since th al Box (Rule 70.2	ey have been conside:	of) the amendments annexed to this report and listed below ered to go beyond the disclosure as filed, as indicated in the		
			description, page claims, Nos.	s			
		∃ the d	drawings, sheets				
	[⊒ tne s ∃ any	sequence listing table(s) related to	(specify): o sequence listing <i>(spe</i>	ecify):		
	* I	f ite	em 4 applies,	some or all of t	these sheets may be marked "superseded."		



International application No. PCT/EP2004/000299

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Yes: Claims 1-10

No: Claims

Inventive step (IS) Yes: Claims 1-10

No: Claims

Industrial applicability (IA) Yes: Claims 1-10

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet



INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)



PCT/EP2004/000299

To section V

The following documents were cited in the search report and were considered for the examination of the present application:

D1: GB-A-1 533 235 (LILLY INDUSTRIES LTD) 22 November 1978

D2: EP-A-0 454 436 (LILLY INDUSTRIES LTD) 30 October 1991

D3: CALLIGARO, D.O. ET AL.: "The Synthesis and Biological Activity of some known and Putative Metabolites of the Atypical Antipsychotic Agent Olanzapine (LY170053)" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 1, 1997, pages 25-30,

The present application deals with a process for the preparation of the CNS-active compound Olanzapine (claims 1-5); furthermore compounds useful as intermediates in this process are claimed (claims 6-10).

Documents D1 (page 10) and D2 (claim 7) anticipate processes which are characterized by a cyclization reaction starting from a phenyl/thienyl amino precursor. In contrast to this the presently claimed process starts from a benzodiazepine intermediate which is subjected to a cyclization reaction using sulfur thus resulting in the formation of the annellated thiophene heterocycle.

Document D3 discloses some derivative sof Olanzapine which are not interfering with claims 6-10.

In view of the aforementioned differences novelty is acknowledged for claims 1-10 (Art. 33(2) PCT).

The description contains data which show that the claimed process results in the formation of the desired target molecule in good yield and purity. Thus the involvement of an inventive step is acknowledged (Art. 33(3) PCT).